HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery

Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition.

Analyst Commentary

Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition. The cluster of target cuts suggests a reset in expectations around what the market should be willing to pay for the stock, even as one firm has cited Vivasure as a positive driver and adjusted its target upward.

On the cautious side, bearish analysts have reduced price targets by double digit dollar amounts in several cases, signaling concerns about how current execution and growth prospects compare with prior assumptions. These moves contrast with a more supportive stance from at least one research firm that lifted its target to US$93 after the Vivasure deal, pointing to potential benefits from the acquired technology and product pipeline.

For you as an investor, the mixed commentary effectively narrows the debate to what is already reflected in the share price. The trimmed consensus fair value around US$74 sits below the most bullish cited target, suggesting that while some see room for value creation tied to Vivasure, others are questioning whether the stock fully earns a higher multiple given perceived risks.

Bearish Takeaways

• Bearish analysts cutting price targets by US$10 to US$18 are signaling that, in their view, prior assumptions on revenue growth, margin resilience, or deal synergies may have been too optimistic.
• The cluster of target reductions around the same time hints at shared concerns about execution risk, including the ability to integrate Vivasure smoothly without disrupting the core business.
• Lower targets suggest some analysts see limited upside at prior valuation levels, raising questions about how much investors should pay relative to the company’s current growth profile and capital allocation plans.
• The gap between the higher US$93 target and the more conservative revised targets highlights uncertainty around how quickly any benefits from Vivasure could translate into earnings, which can influence sentiment if progress is slower than expected.

What’s in the News

• Haemonetics issued earnings guidance for the first quarter of 2026, with total revenue expected between US$300 million and US$310 million and product revenue between US$171 million and US$176 million (company guidance).
• For the full year 2026, Haemonetics guided to total revenue in a range of US$1.215b to US$1.255b, giving investors a sense of the scale of the business it is targeting for the year (company guidance).
• Full year 2026 product bookings are expected to be between US$510 million and US$560 million, which may help you gauge how management is thinking about demand for its products across the year (company guidance).

Valuation Changes

• Fair Value Estimate was reduced slightly from about US$74.82 to about US$74.00, tightening the implied upside investors might use as a reference point.
• The Discount Rate was nudged up from about 8.52% to about 8.61%, which can modestly lower the present value of future cash flows in valuation models.
• Revenue Growth was adjusted modestly higher from about 4.69% to about 4.93%, reflecting a slightly stronger outlook for top line expansion in the model inputs.
• The Net Profit Margin edged down from about 16.13% to about 15.96%, indicating a small reduction in expected profitability assumptions.
• The Future P/E was held broadly steady, moving from about 14.40x to about 14.44x, suggesting little change in the multiple applied to projected earnings.